Montelukast Rudipharm (Montelukast Sodium)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1 on cells in the respiratory tract. By antagonizing this receptor, it inhibits leukotriene‑mediated bronchoconstriction, vascular leakage and inflammatory cell recruitment, thereby decreasing airway swelling and hyper‑responsiveness.

The appropriate dose of Montelukast is determined by the prescribing healthcare professional based on the patient’s age, condition and clinical response. Dosage regimens may differ for asthma, allergic rhinitis or exercise‑induced bronchoconstriction, and should follow the prescriber’s instructions.

Safety data for Montelukast during pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against possible risks and discuss any concerns with the patient. Women who are pregnant, planning pregnancy or breastfeeding should consult their physician before using the medication.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Montelukast Rudipharm. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists for maintenance therapy. While inhaled steroids directly reduce airway inflammation, Montelukast provides a convenient once‑daily tablet that specifically blocks leukotriene pathways, which can be advantageous for patients preferring oral medication.

Montelukast Rudipharm should be stored at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight and excessive heat. Do not store in the bathroom or near a kitchen sink where humidity is high.

Montelukast is taken orally, usually as a tablet that should be swallowed whole with water. It is generally taken once daily in the evening, but patients should follow the specific timing advised by their prescriber. The tablet should not be chewed, crushed or split unless directed by a healthcare professional.

Serious adverse events include allergic reactions such as rash, urticaria, angioedema or anaphylaxis, as well as neuropsychiatric effects like mood changes, depression, or suicidal thoughts. Rarely, liver enzyme elevations may occur. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast should be avoided in individuals with a known hypersensitivity to Montelukast Sodium or any of the tablet’s excipients. It is also not appropriate as a rescue medication for acute asthma attacks. Patients with severe liver disease or uncontrolled psychiatric conditions should discuss alternative therapies with their clinician.